Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials
Top Cited Papers
Open Access
- 30 January 2025
- journal article
- review article
- Published by Elsevier in Obesity Pillars
- Vol. 13, 100162
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2022YFC3502000)
- National Natural Science Foundation of China (82174229)
This publication has 33 references indexed in Scilit:
- Semaglutide for the treatment of obesityTrends in Cardiovascular Medicine, 2023
- Tirzepatide: First ApprovalDrugs, 2022
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic diseaseMolecular Metabolism, 2021
- ObesityJACC, 2018
- Obesity pandemic: causes, consequences, and solutions—but do we have the will?Fertility and Sterility, 2017
- Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health ProblemCurrent Obesity Reports, 2015
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 DiabetesCurrent Atherosclerosis Reports, 2014
- Risk of pancreatitis in patients treated with incretin-based therapiesDiabetologia, 2014
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonistsDiabetes Research and Clinical Practice, 2014
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006